SCHEMBL2206431

SCHEMBL2206431

CC(C)CN(CC(C)C)P(=O)(Cl)Cl

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
PIK3CD O00329 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9452614 0.83 CA12 (0.37) CA12CA1CA2CA9PIK3CD
SCHEMBL3889745 0.72 CA12 (0.37) CA12CA1CA2CA9PIK3CD
SCHEMBL5392828 0.72 CA12 (0.42) CA12CA1CA2CA9PIK3CD
SCHEMBL9876483 0.70 CA12 (0.37) CA12CA1CA2CA9
SCHEMBL379577 0.67
SCHEMBL18245272 0.65 CA12 (0.36) CA12CA1CA2CA9
SCHEMBL29062254 0.63 ALDH1A1 (0.41) CA12CA1CA2CA9TRPM8
SCHEMBL9503075 0.63 FDPS (0.37) CA12CA1CA2
SCHEMBL14312089 0.63 TRPM8 (0.48) CA1TRPM8
SCHEMBL18244853 0.62 CA12 (0.30) CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 US claimed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 EP claimed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 US claimed
US-20250243540-A1 PROBE RELATED REAGENTS AND METHODS BRENTANO BIOTECHNOLOGY ASSOCIATES (US) 2025-07-31 US disclosed
EP-4034131-A1 DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES Brentano Biotechnology Associates (US) 2022-08-03 EP disclosed
US-20220073546-A1 DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES BRENTANO BIOTECHNOLOGY ASSOCIATES (US) 2022-03-10 US disclosed
WO-2021061154-A1 DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES BRENTANO BIOTECHNOLOGY ASSOCIATES (US) 2021-04-01 WO disclosed
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 US disclosed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 US disclosed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 EP disclosed
EP-1795208-B1 Glycerophosphoric acid ester derivative having polyfunctional metal chelate structure FUJIFILM CORP (JP) 2011-07-27 EP disclosed
US-5643948-A ANTIINFLAMMATORY, ANTICANCER PROCYON PHARMACEUTICALS, INC. (US) 1997-07-01 US disclosed
US-5585481-A VERSATILITY; NON-NUCLEOTIDE MONOMERIC UNIT HAVING A LIGAND AND FIRST AND SECOND COUPLING GROUPS WHICH ARE LINKED TO THE NON-NUCLEOTIDE MONOMERIC UNIT ; LABELS, INTERCALATORS, PROBES GEN-PROBE INCORPORATED (US) 1996-12-17 US disclosed
EP-0313219-B1 Non-nucleotide linking reagents for nucleotide probes GEN PROBE INC (US) 1996-05-08 EP disclosed
US-5324631-A Spectrum analysis of amplified hybrid products produced by contacting various fluorescent-labelled primers with the genomic DNA, particularly that of plants PIONEER HI-BRED INTERNATIONAL, INC. 1994-06-28 US disclosed
EP-0370317-B1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-CHLOROPYRIDINES BAYER AG (DE) 1993-06-02 EP disclosed
US-5145842-A Protein kinase c. modulators. d. ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) 1992-09-08 US disclosed
WO-1992002484-A1 PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) 1992-02-20 WO disclosed
EP-0370317-A1 Process for the preparation of substituted 2-chloropyridines BAYER AG (DE) 1990-05-30 EP disclosed
EP-0313219-A2 Non-nucleotide linking reagents for nucleotide probes GEN-PROBE INCORPORATED (US) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151002-A1 Guggulphospholipid Methods and Compositions SGMS2, SGMS1, PLA2G5 CA12 3093/4885CA1 3241/4885CA2 4036/4885
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS SGMS1, SGMS2, GGPS1 CA12 2532/4885CA1 2522/4885CA2 2837/4885
US-20250243540-A1 PROBE RELATED REAGENTS AND METHODS DNTT, NCL, NT5C3B CA12 1803/4885CA1 2366/4885CA2 2855/4885
US-20220073546-A1 DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES NCL, PCNA, DNTT CA12 3596/4885CA1 3599/4885CA2 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.